Inulin for Infections in the Intensive Care Unit : Prebiotic Inulin to Limit Antimicrobial-Resistant Infections During Critical Illness: A Phase II Clinical Trial
The proposed trial hypothesizes that inulin maintains short-chain fatty acid (SCFA)-producing colonic anaerobes and that these bacteria are protective against multi-drug resistant organism (MDRO) colonization and subsequent MDR infection. Inulin, a vegetable-derived non-digestible polysaccharide is well established as the key nutrient source for SCFA-producing bacteria. Previous human studies have shown that (1) inulin increases levels of SCFA producers and SCFAs and (2) that this increase correlates with improved colonic mucosal integrity and resistance to MDR pathogens. In animal studies, inulin improves survival after pathogen challenge or injection with lipopolysaccharide. The overall aim of this clinical trial is to determine whether inulin improves gut colonization resistance against antibiotic-resistant pathogens and therefore prevents antibiotic-resistant infections in the setting of critical illness. To accomplish this, 90 critically ill adults who are receiving broad-spectrum antibiotics will be blindly randomized 1:1:1 to receive placebo, inulin 8 g twice daily, or inulin 16 g twice daily for a minimum of 7 days, with bedside follow-up extending to 30 days or hospital discharge..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
ClinicalTrials.gov - (2024) vom: 31. Jan. Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: March 7, 2019, Last downloaded: ClinicalTrials.gov processed this data on February 07, 2024, Last updated: February 07, 2024 |
---|
Study ID: |
NCT03865706 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG002990490 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG002990490 | ||
003 | DE-627 | ||
005 | 20240207010519.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG002990490 | ||
035 | |a (UBBS_Klinische_Studien)NCT03865706 | ||
035 | |a (UBBS_Klinische_Studien)AAAS2576 | ||
035 | |a (UBBS_Klinische_Studien)PR181960 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Inulin for Infections in the Intensive Care Unit |b Prebiotic Inulin to Limit Antimicrobial-Resistant Infections During Critical Illness: A Phase II Clinical Trial |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: March 7, 2019, Last downloaded: ClinicalTrials.gov processed this data on February 07, 2024, Last updated: February 07, 2024 | ||
520 | |a The proposed trial hypothesizes that inulin maintains short-chain fatty acid (SCFA)-producing colonic anaerobes and that these bacteria are protective against multi-drug resistant organism (MDRO) colonization and subsequent MDR infection. Inulin, a vegetable-derived non-digestible polysaccharide is well established as the key nutrient source for SCFA-producing bacteria. Previous human studies have shown that (1) inulin increases levels of SCFA producers and SCFAs and (2) that this increase correlates with improved colonic mucosal integrity and resistance to MDR pathogens. In animal studies, inulin improves survival after pathogen challenge or injection with lipopolysaccharide. The overall aim of this clinical trial is to determine whether inulin improves gut colonization resistance against antibiotic-resistant pathogens and therefore prevents antibiotic-resistant infections in the setting of critical illness. To accomplish this, 90 critically ill adults who are receiving broad-spectrum antibiotics will be blindly randomized 1:1:1 to receive placebo, inulin 8 g twice daily, or inulin 16 g twice daily for a minimum of 7 days, with bedside follow-up extending to 30 days or hospital discharge. | ||
650 | 2 | |a Infections | |
650 | 2 | |a Communicable Diseases | |
650 | 2 | |a Cross Infection | |
650 | 2 | |a Nutrition Disorders | |
650 | 2 | |a Critical Illness | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Active, not recruiting | |
650 | 4 | |a Phase: Phase 2 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 31. Jan. |
773 | 1 | 8 | |g year:2024 |g day:31 |g month:01 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT03865706 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2024 |b 31 |c 01 |